On May 19, 2023, TG Therapeutics Inc. (NASDAQ: TGTX) opened at $30.75, lower -2.25% from the last session. During the day, the shares moved up to $30.84 and dropped to $29.52 before settling in for the closing price of $30.64. Price fluctuations for TGTX have ranged from $3.48 to $35.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 78.80% annually for the last half of the decade. Company’s average yearly earnings per share was noted 44.40% at the time writing. With a float of $133.34 million, this company’s outstanding shares have now reached $140.31 million.
In an organization with 237 employees, it is important to assess its efficiency. In terms of profitability, gross margin is +71.99, operating margin of -6924.20, and the pretax margin is -7121.54.
TG Therapeutics Inc. (TGTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of TG Therapeutics Inc. is 1.10%, while institutional ownership is 69.70%. The most recent insider transaction that took place on Jan 06, was worth 95,760. In this transaction Director of this company bought 9,000 shares at a rate of $10.64, taking the stock ownership to the 201,848 shares. Before that another transaction happened on Jan 04, when Company’s Director sold 30,000 for $11.10, making the entire transaction worth $333,000. This insider now owns 234,729 shares in total.
TG Therapeutics Inc. (TGTX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 3/30/2023, the company posted -$0.28 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.37) by $0.09. This company achieved a net margin of -7121.54 while generating a return on equity of -134.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.40% per share during the next fiscal year.
TG Therapeutics Inc. (NASDAQ: TGTX) Trading Performance Indicators
Check out the current performance indicators for TG Therapeutics Inc. (TGTX). In the past quarter, the stock posted a quick ratio of 2.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 532.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.23, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of TG Therapeutics Inc. (TGTX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.66 million. That was inferior than the volume of 4.61 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.85%. Additionally, its Average True Range was 1.94.
During the past 100 days, TG Therapeutics Inc.’s (TGTX) raw stochastic average was set at 80.13%, which indicates a significant increase from 12.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.09% in the past 14 days, which was lower than the 97.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.18, while its 200-day Moving Average is $12.78. However, in the short run, TG Therapeutics Inc.’s stock first resistance to watch stands at $30.69. Second resistance stands at $31.42. The third major resistance level sits at $32.01. If the price goes on to break the first support level at $29.37, it is likely to go to the next support level at $28.78. Assuming the price breaks the second support level, the third support level stands at $28.05.
TG Therapeutics Inc. (NASDAQ: TGTX) Key Stats
There are currently 149,396K shares outstanding in the company with a market cap of 4.58 billion. Presently, the company’s annual sales total 2,790 K according to its annual income of -198,340 K. Last quarter, the company’s sales amounted to 7,800 K and its income totaled -39,230 K.
